MRKR Marker Therapeutics Inc

$MRKR You say you're going to do a data release in Q2. We give you the benefit of the doubt and think maybe you mean "data through Q2." But now q3 is almost over. Your IR says, effectively, it's important to get the data "right." We could be frustrated. That aside, this all seems a bit odd. Maybe it's data analysis, trying to figure out what's going on. Maybe it's something else. What's going on?

$MRKR I think we are better off just holding for a few more months because two major cancer conferences are coming up and companies usually release data around the first week of November. that’s what I feel will happen with MRKR. hopefully it works out for all of us.🙏🏼🙏🏼🙏🏼

$MRKR Their PR reminds me of the old parent advice, “if you don’t have anything nice [good] to say, don’t say anything at all.”

$MRKR Nevermind, they are likely waiting on FDA feedback on pivotal trial design (extension into 2b) and or data to support that design or path forward. I suspect the two are linked.

$MRKR i’m taking a guess and I’m predicting we get data the first two weeks of November

$MRKR they are accepting low asks i tried a few and all went thru. more sellers than buyers at the moment. Retail is fighting it out.

$MRKR Only in phase 1 of MT- 601 trial….. I see further financing/ dilution needs in the coming year….. am I wrong? I’m thinking what money I still have left in this dog, can be better utilized elsewhere- and before further erosion.

$MRKR I share your frustration. I’ve also held onto this stock for years only to see it go quiet and trend down. But despite the radio silence, some spooky feeling give me confidence that the Phase 1 results will bring this company to the market’s attention. The interim results of 66% ORR in a refractory setting, 50% CR rate in Non-Hodgkin Lymphoma, as well as 78% ORR in Hodgkin Lymphoma are very encouraging with responses lasting 3 to 24+ months now. So far they have demonstrated that the multi-antigen targeted T-cells are persisting and continuing to clear or suppress disease with zero neurotoxicity and no dose-Limiting toxicities. It’s very possible this is flying way under the radar. Fingers crossed the full Phase 1 gives us the similar results. The silence could be to do with getting the final data ready for an industry announcement or publication, in my opinion.

$MRKR im sitting with an average around 4 and i think the end is near. Insolvency or reverse split. That's like lethal injection or firing squad.

$MRKR Vera emerged from his cave to congratulate a partner but he cannot get a compliment returned since he got nothing! Zero. nada. zilch.

$MRKR i’m trying to stay positive, but did they have to lockdown the manufacturing process before they can move on and only do a phase 2 trial? would this satisfy the FDA? thank you for any opinions.